New mRNA vaccine trial aims to stop genital herpes
NCT ID NCT07330440
First seen Jan 10, 2026 · Last updated Jun 18, 2026 · Updated 33 times
Summary
This early-stage study is testing an mRNA vaccine designed to protect against genital herpes (HSV-2) in 144 healthy adults aged 18 to 55. The vaccine is given in different doses to people who have and have not been exposed to the virus before. The main goal is to check for side effects and see how well the vaccine triggers an immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENITAL HERPES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Jishuitan Hospital
Beijing, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.